Samsung Electronics chief heads to Washington to support US trade talks, Yonhap says
Yonhap said Lee is expected to support trade talks between South Korea and the United States during the trip.
擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
SEC Approves In-Kind Crypto ETF Redemptions
The Securities and Exchange Commission voted Tuesday to approve in-kind creations and redemptions for crypto exchange-traded funds, marking a departure from the cash-only structure previously required for spot Bitcoin and Ethereum ETFs, according to an SEC press release. The approval brings crypto ETFs in line with other commodity-based ETFs approved by the Commission, allowing authorized participants to deliver or receive the underlying Bitcoin or Ether assets directly rather than transacting exclusively in cash, according to the SEC. Invest in Gold American Hartford Gold: #1 Precious Metals Dealer in the Nation Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Thor Metals Group: Best Overall Gold IRA The approval addresses what Federico Brokate, head of U.S. business at 21Shares, called "a long-standing structural barrier that has limited scalability and cost efficiency for investors." The change is expected to enhance market efficiency and reduce investor costs "Investors will benefit from these approvals, as they will make these products less costly and more efficient," said SEC Chairman Paul S. Atkins in the press release. In-Kind Structure Reduces Costs The new structure enhances primary market efficiency, improves secondary market spreads, and strengthens overall price discovery, according to Brokate. In-kind functionality also gives market makers and liquidity providers greater flexibility to manage risk during periods of heightened volatility. Previously approved spot Bitcoin and Ethereum ETFs were limited to creations and redemptions on an in-cash basis, according to the SEC. The cash-only requirement created operational inefficiencies that distinguished crypto ETFs from traditional commodity-based products. Jamie Selway, director of the Division of Trading and Markets, said the decision provides "flexibility and cost savings to ETP issuers, authorized participants, and investors, resulting in a more efficient market," according to the SEC release. 21Shares has "long operated in-kind models across our global ETP platform" and has seen firsthand how they reduce costs for investors, Brokate said. He views this as "a foundational development that will accelerate the next phase of crypto ETF adoption in the U.S." SEC Ramps Up Crypto Agenda The Commission also approved other crypto-related orders, including exchange applications for mixed Bitcoin-Ether ETPs and options on certain spot Bitcoin ETFs, according to the SEC. The regulatory change reflects what Atkins called "a new day at the SEC" and his priority of "developing a fit-for-purpose regulatory framework for crypto asset markets," according to the press | © Copyright 2025 All rights reserved
Yahoo
28 minutes ago
- Yahoo
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase. The company reported earnings per American Depositary Share (EPADS) of 52 cents, surpassing analyst expectations of 47 cents. However, in yen terms, earnings per share (EPS) experienced a 14.1% decline, or a 10% decrease when adjusted for constant currency, reaching 151 yen. Total sales for the quarter amounted to $7.66 billion (1.11 trillion yen), exceeding consensus estimates of $7.53 billion. Despite this positive top-line performance, Takeda faced challenges on the bottom line, with core net profit dropping by 14.4% (or 10.3% at constant currency) to 237 billion key factor behind this decline was the significant erosion of revenue from Vyvanse, its attention-deficit hyperactivity disorder (ADHD) treatment, following the introduction of generic competition. This decline was anticipated by the company and was a major contributor to both the revenue drop and a reduction in core operating profit. View more earnings on TAK U.S. sales of Vyvanse fell 53.8% at constant exchange rates, dropping to 57.9 billion yen. The generics' market entry led to an overall sales decline of 46.9% for the drug during the quarter. On a more positive note, Takeda's portfolio of rare disease treatments showed resilience. Sales of Takhzyro, a treatment for hereditary angioedema, rose by 3.7% to 55.1 billion yen. Immunoglobulin sales also saw growth, increasing 2% at constant currency to 194 billion yen, while Albumin sales surged 16.2%, reaching 32.2 billion yen. In the vaccine segment, Takeda's Qdenga dengue vaccine experienced a 4.8% decline in sales at constant currency, amounting to 8.8 billion yen. However, the oncology division performed solidly, with Adcetris sales climbing 13.2% to 37.2 billion yen, while Fruzaqla, a novel therapy for certain cancers, saw a more modest growth of 8.9%, reaching 12.3 billion yen. Takeda's operating profit for the quarter rose 11% to 184.6 billion yen, while core operating profit dropped 15.8% (down 11.9% on a constant currency basis) to 321.8 billion yen. This decrease was primarily due to lower year-over-year impairment and restructuring expenses. Milano Furuta, Takeda's CFO, commented on the results, noting, 'The impact of Vyvanse generic erosion on Takeda's FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May.' Outlook Takeda reaffirms its fiscal 2025 guidance, with core revenue of 4.53 trillion yen and core operating profit broadly flat at 1.14 trillion yen, and core earnings of 485 yen. Price Action: TAK stock is trading lower by 4.99% to $13.61 at last check Wednesday. Read Next:Photo by Veroniksha via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Traders scale back expectations for September rate cut following Powell comments
-- Traders have sharply reduced their expectations for a Federal Reserve rate cut in September following today's FOMC statement, keeping rates steady, and remarks from Fed Chair Jerome Powell. CME 30-Day Fed Fund futures now reflect just a 45.7% probability of a rate cut in September, down from 63.4% prior to the release of the statement. The declining odds come despite support from two Fed officials, Michelle Bowman and Christopher Waller, who both favored lowering the federal funds rate target range by a quarter percentage point this month. During his post-meeting press conference, Powell addressed concerns about the inflationary impact of tariffs. 'A reasonable base case is that the effects on inflation could be short lived, reflecting a one-time shift in the price level, but it is also possible that the inflationary effects could instead be more persistent, and that is a risk to be assessed and managed,' Powell said. Powell added that services inflation is coming down nicely, while inflation on goods is going higher because of the tariffs. The reluctance of Powell to cut rates has led to harsh criticism from President Trump, who said he is costing the government billions of dollars in excess debt servicing costs. It is widely expected that he will be replaced when his term is up next May. Related articles Traders scale back expectations for September rate cut following Powell comments Surge of 50% since our AI selection, this chip giant still has great potential If Powell goes, does Fed trust go with him? Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
